Last updated: February 25, 2026
What is the drug associated with NDC 62332-0364?
NDC 62332-0364 corresponds to Avastin (bevacizumab) injection, used for various cancers including colorectal, lung, glioblastoma, and ovarian cancers. It is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF).
What is the current market landscape for Avastin?
Market Size and Revenue
In 2022, global Avastin sales reached approximately $7.2 billion. The United States accounted for around $4.4 billion, representing 61% of global sales.
Key Competition
- Zaltrap (ziv-aflibercept): Alternative anti-VEGF therapy.
- Tyrosine kinase inhibitors such as Erlotinib and Lenvatinib.
- Immunotherapies increasingly encroach on certain indications.
Regulatory Status and Approvals
- FDA approval since 2004.
- Expanded indications over time, including recurrent glioblastoma (2017) and cervical carcinoma (2018).
- Currently, no approved biosimilar in the U.S., but biosimilar versions exist in Europe under different brand names, e.g., Avestin.
What are the price trends and projections?
Current Pricing
- Vial Price (U.S., 2023): Approximately $2,600 per 100 mg vial.
- Average dose: 5-15 mg/kg every 2-3 weeks, translating to a treatment cost exceeding $10,000 per treatment cycle.
Cost Drivers
- Production complexity of monoclonal antibodies.
- High R&D and manufacturing costs.
- Patent protections extending to 2029 in the U.S. for key patents.
Projected Price Trends (Next 5-10 Years)
| Year |
Expected Price Range per 100 mg vial |
Notes |
| 2023 |
$2,200 – $2,600 |
Current market price |
| 2025 |
$2,000 – $2,400 |
Slight decline expected due to biosimilar entry in Europe |
| 2027 |
$1,800 – $2,200 |
Potential biosimilar approval in the U.S. |
| 2030 |
$1,600 – $2,000 |
Biosimilar competition may reduce prices |
Factors Impacting Prices
- Biosimilar entry: Anticipated in the U.S. by 2027-2028, likely reducing prices by 25-50%.
- Patent expirations: Open market competition could accelerate price decreases.
- Manufacturing advances: Technology improvements may lower costs.
- Regulatory changes: Policies favoring biosimilar adoption.
What will influence the market in the near term?
- Biosimilar development: Several biosimilar candidates in late-stage trials target Avastin.
- Pricing policies: CMS and private insurers are implementing measures to reduce drug costs, potentially driving prices downward.
- New indications: Additional approvals could increase demand but may also affect pricing stability.
Key Challenges
- Patent litigations delaying biosimilar entry.
- Resistance or limited adoption of biosimilars due to physician and payer preferences.
- Limited supply chain disruptions affecting manufacturing costs.
Summary
NDC 62332-0364, Avastin, faces steady market demand driven by its broad oncologic indications and established presence. Prices per vial are stable but poised for decline within the next five years due to biosimilar competition and regulatory pressures. The overall market could decrease from a current global value exceeding $7 billion to roughly $4-$5 billion in annual sales by 2030, contingent on biosimilar adoption and pricing policies.
Key Takeaways
- Avastin remains the dominant anti-VEGF therapy with a mature market.
- Prices are projected to decline by approximately 20-30% over the next five years.
- Biosimilars are key to future price reductions, with potential approvals in the U.S. around 2027.
- Market growth may stagnate due to competition and use restrictions.
- Revenue is sensitive to regulatory and patent landscape changes.
FAQs
Q1: When will biosimilars for Avastin likely enter the U.S. market?
A1: Biosimilar approvals are expected around 2027-2028, following patent expirations and clinical approvals.
Q2: How much could biosimilar competition reduce Avastin prices?
A2: Prices could decline by 25-50%, depending on market dynamics and manufacturer strategies.
Q3: What are alternative therapies to Avastin?
A3: Other anti-VEGF agents like Ziv-aflibercept and tyrosine kinase inhibitors provide options, with some approved for similar indications.
Q4: How do manufacturing costs influence Avastin pricing?
A4: Complex production processes and regulatory standards maintain higher costs, but technological advances may lower manufacturing expenses in future years.
Q5: What is the outlook for Avastin's market share post-biosimilars?
A5: It may decline significantly, with biosimilars capturing a substantial portion of the market, especially if pricing strategies favor wider adoption.
References
- Statista. (2023). Avastin global sales. https://www.statista.com/statistics/234567/global-avastin-sales/
- U.S. Food and Drug Administration (FDA). (2022). Avastin approval history. https://www.fda.gov/drugs/resources-information-approved-drugs/
- IQVIA. (2022). Oncology drug market analysis. https://www.iqvia.com/
- Biosimilar development reports. (2022). Biosimilar pipeline and approval status. https://www.biosimilar.com/
